Patents Examined by Yong Chu
  • Patent number: 10077236
    Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: September 18, 2018
    Assignees: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Patent number: 10076511
    Abstract: The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (IPF), emphysema of the lungs, chronic obstructive pulmonary disease (COPD) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on Treamide. The latter is a bisamide derivative of dicarboxylic acid of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Treamid Therapeutics GmbH
    Inventors: Vladimir Evgenievich Nebolsin, Anastasia Vladimirovna Rydlovskaya, Alexandr Mikhailovich Dygai, Tatiana Gennadievna Borovskaya, Evgenii Germanovich Skurikhin
  • Patent number: 10053451
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 21, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
  • Patent number: 10034881
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Patent number: 10022355
    Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment of REM sleep behavior disorder.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 17, 2018
    Assignee: Axovant Sciences GmbH
    Inventors: Lawrence Tim Friedhoff, Shankar Ramaswamy, Yandong Wen
  • Patent number: 10015960
    Abstract: A sticker adjuvant that may be used in agrochemical compositions is disclosed. The sticker adjuvant is a polyether amide or a polyether imide formed by the reaction of a polyether polyamine with a polyfunctional monomer. The polyfunctional monomer may be a polyacid, a di-functional acyl halide, an acid anhydride, a poly(acid anhydride) and a mixture thereof.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 10, 2018
    Inventors: Matthew T. Meredith, Alan J Stern, Dilek Saylik
  • Patent number: 10004233
    Abstract: The present invention relates to water treatment. In one embodiment there is provided a method of treating an aqueous system to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method comprises adding treatment agents to said aqueous system and wherein said treatment agents comprise: (a) a phosphonium compound; and (b) an oxazolidine compound.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 26, 2018
    Assignee: BWA Water Additives UK Limited
    Inventor: Jeffrey Frank Kramer
  • Patent number: 10004761
    Abstract: A composition suitable for treating a variety of medical, aesthetic and cosmetic conditions in mucous membranes and occluded skin areas, comprising hyaluronic acid, N-acetylcysteine, an active agent and set to pH of less than 6, which is characterized by high in vivo stability, is disclosed, as well as uses thereof in temporally extended delivery of active agent to mucous membrane in bodily sites.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 26, 2018
    Inventors: Mark M. Levy, Zvi Nevo, Samuel Levin
  • Patent number: 10000524
    Abstract: A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C1-C5 alkyl group, preferably a methyl group, or a C7-C12 benzylic group, preferably a benzyl group. This process is particularly suitable to industry.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 19, 2018
    Assignee: Donesta Bioscience B.V.
    Inventors: Mark Theodoor Verhaar, Thomas Koch, Erwin Gerardus Jacobus Warmerdam
  • Patent number: 9993492
    Abstract: The present invention refers to a compound selected from the group consisting of a lysophospholipid and a lysophospholipid analog for use in the treatment or prophylaxis of honeybee brood diseases, in particular American foulbrood and European foulbrood. The invention also refers to a diet composition, a sprayable composition, a dipping solution for brood combs, a beeswax composition and liposomal and microsphere- or nanosphere-based compositions, comprising a compound according to the invention, for use in the treatment or prophylaxis of bee brood diseases.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: June 12, 2018
    Assignee: University of Graz
    Inventors: Wolfgang Schühly, Ulrike Riessberger-Gallé, Javier Hernández-López, Karl Crailsheim
  • Patent number: 9988395
    Abstract: The present disclosure relates generally to systems, methods, and compounds for therapeutic use against parasitic infections. More particularly, the disclosure relates to anti-parasitic compounds, and methods for making and for using the anti-parasitic compounds, where the anti-parasitic compounds have the general formula: where X, R1, R2, R3, R4, R5, and R6 are defined more fully below.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: June 5, 2018
    Inventors: Rachid Skouta, Rosa A. Maldonado
  • Patent number: 9988589
    Abstract: The present invention relates to novel acid-free quaternized nitrogen compounds, to the preparation thereof and to the use thereof as a fuel and lubricant additive, more particularly as a detergent additive, as a wax antisettling additive (WASA) or as an additive for reducing internal diesel injector deposits (IDID); to additive packages which comprise these compounds; and to fuels and lubricants thus additized. The present invention further relates to the use of these acid-free quaternized nitrogen compounds as a fuel additive for reducing or preventing deposits in the injection systems of direct-injection diesel engines, especially in common-rail injection systems, for reducing the fuel consumption of direct-injection diesel engines, especially of diesel engines with common-rail injection systems, and for minimizing power loss in direct-injection diesel engines, especially in diesel engines with common-rail injection systems.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 5, 2018
    Assignee: BASF SE
    Inventors: Wolfgang Grabarse, Harald Boehnke, Christian Tock, Cornelia Roeger-Goepfert, Ludwig Voelkel
  • Patent number: 9987278
    Abstract: Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 5, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Tomoki Naoe, Hitoshi Kiyoi, Shinji Hagiwara, Masaru Takasaki, Daisuke Hirano, Toshiyuki Nakatani, Takeshi Yamaura
  • Patent number: 9974771
    Abstract: Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: May 22, 2018
    Inventors: Hermann M. Schaetzl, Basant Abdulrahman, Sabine Gilch, Alexander Zukiwski, Stefan Proniuk
  • Patent number: 9963413
    Abstract: The process relates improving terephthalic acid purge filtration rate by controlling % water in filter feed slurry and to the recovery of a metal catalyst from an oxidizer purge stream produced in the synthesis of carboxylic acid, typically terephthalic acid, while utilizing pressure filtration.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: May 8, 2018
    Assignee: Grupo Petrotemex, S.A. de C.V.
    Inventors: Kenny Randolph Parker, Larry Wayne Blair
  • Patent number: 9963447
    Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 8, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Jessica L. Wall
  • Patent number: 9962421
    Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 8, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: T. G. Sambandan, ChoKyun Rha, Anthony J. Sinskey, Ravigadevi Sambanthamurthi, Yew Ai Tan, Kalyana Sundram P. Manickam, Mohd Basri Wahid
  • Patent number: 9962353
    Abstract: The present invention relates to use of a tall oil fatty acid and/or a tall oil fatty acid which is modified by saponification in binding toxins.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: May 8, 2018
    Assignee: Hankkija Oy
    Inventor: Juhani Vuorenmaa
  • Patent number: 9949970
    Abstract: Disclosed are compounds of general formula A useful as potential anti-tubercular agents.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: April 24, 2018
    Inventors: Ahmed Kamal, Rajesh Vcrnc Shetti, Ponnampalli Swapna, Shaik Azeeza, A. Malla Reddy, Inshad Ali Khan, Sheikh Tasduq Abdullah, Sandeep Sharma, Nitin Pal Kalia
  • Patent number: 9913842
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 13, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander Rossi